---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-098059"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2024-09-09T23:59:59+00:00"
generated_at: "2026-05-31T05:57:02.691644+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ArriVent: firmonertinib shows 81.8% ORR in EGFR PACC mutant NSCLC Phase 1b data

## Summary
- 81.8% ORR and 63.6% confirmed ORR by BICR at 240mg dose in first-line EGFR PACC mutant NSCLC.
- 46.2% confirmed CNS ORR (6/13) in patients with brain metastases at baseline.
- Median duration of response not reached; 90.9% (20/22) of confirmed responders remain on study.
- No Grade 4/5 TRAEs or treatment discontinuations due to TRAEs; safety consistent with prior data.
- Data presented at WCLC 2024; ArriVent plans virtual webinar on September 9, 2024 at 4:30pm ET.

## SEC filing metadata
- accession: 0001104659-24-098059
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2024-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465924098059/0001104659-24-098059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465924098059/tm2423588d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-098059
- JSON: https://secwatch.observer/filing/0001104659-24-098059.json
- Plain text: https://secwatch.observer/filing/0001104659-24-098059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.